NewAmsterdam Pharma Company N.V. (NAMS)

NewAmsterdam Pharma Company N.V. is trading at $20.06, down 3.37% on the session. The 50 day average sits at $22.86 and the 200 day at $29.80, which puts the stock in a downtrend. RSI is at 40.7, which reads as weak, and MACD is bullish crossover. Volume is below average.

The nearest support is around $19.58 with resistance near $22.29, so that band frames the current range. Average daily movement is roughly $1.22, or about 6.1% of the share price, which is what any stop placement has to allow for. The overall health score of 27 out of 100 combines a trend score of 0, momentum of 44 and a risk score of 48.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.